CN105130998A - 库潘尼西的制备方法 - Google Patents
库潘尼西的制备方法 Download PDFInfo
- Publication number
- CN105130998A CN105130998A CN201510618067.6A CN201510618067A CN105130998A CN 105130998 A CN105130998 A CN 105130998A CN 201510618067 A CN201510618067 A CN 201510618067A CN 105130998 A CN105130998 A CN 105130998A
- Authority
- CN
- China
- Prior art keywords
- preparation
- pannixi
- morpholine
- base propoxy
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/10—Spiro-condensed systems
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510618067.6A CN105130998B (zh) | 2015-09-25 | 2015-09-25 | 库潘尼西的制备方法 |
PCT/CN2016/088091 WO2017049983A1 (zh) | 2015-09-25 | 2016-07-01 | 库潘尼西的制备方法 |
KR1020187011225A KR102104957B1 (ko) | 2015-09-25 | 2016-07-01 | 코판리십의 제조방법 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510618067.6A CN105130998B (zh) | 2015-09-25 | 2015-09-25 | 库潘尼西的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105130998A true CN105130998A (zh) | 2015-12-09 |
CN105130998B CN105130998B (zh) | 2017-07-28 |
Family
ID=54716625
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510618067.6A Active CN105130998B (zh) | 2015-09-25 | 2015-09-25 | 库潘尼西的制备方法 |
Country Status (3)
Country | Link |
---|---|
KR (1) | KR102104957B1 (und) |
CN (1) | CN105130998B (und) |
WO (1) | WO2017049983A1 (und) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017049983A1 (zh) * | 2015-09-25 | 2017-03-30 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
CN108884496A (zh) * | 2016-02-01 | 2018-11-23 | 拜耳制药股份公司 | Copanlisib生物标志物 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0326307A2 (en) * | 1988-01-23 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
JP2003252875A (ja) * | 2002-03-04 | 2003-09-10 | Lotte Co Ltd | 新規プリン誘導体 |
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5210558B2 (ja) | 2007-07-12 | 2013-06-12 | 株式会社ブリヂストン | 防振装置 |
EP3018131A1 (en) | 2014-11-07 | 2016-05-11 | Bayer Pharma Aktiengesellschaft | Synthesis of copanlisib and its dihydrochloride salt |
CN105130997B (zh) * | 2015-09-25 | 2017-12-05 | 苏州明锐医药科技有限公司 | 一种库潘尼西的制备方法 |
CN105130998B (zh) * | 2015-09-25 | 2017-07-28 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
-
2015
- 2015-09-25 CN CN201510618067.6A patent/CN105130998B/zh active Active
-
2016
- 2016-07-01 KR KR1020187011225A patent/KR102104957B1/ko active IP Right Grant
- 2016-07-01 WO PCT/CN2016/088091 patent/WO2017049983A1/zh active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0326307A2 (en) * | 1988-01-23 | 1989-08-02 | Kyowa Hakko Kogyo Co., Ltd. | Novel pyridazinone derivatives and pharmaceutical preparations containing them |
JP2003252875A (ja) * | 2002-03-04 | 2003-09-10 | Lotte Co Ltd | 新規プリン誘導体 |
CN1688582A (zh) * | 2002-09-30 | 2005-10-26 | 拜尔药品公司 | 稠合吡咯-嘧啶衍生物 |
CN101631464A (zh) * | 2006-12-05 | 2010-01-20 | 拜耳先灵医药股份有限公司 | 用于治疗过度增殖疾病和血管发生相关性疾病的2,3-二氢咪唑并[1,2-c]喹唑啉取代衍生物 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2017049983A1 (zh) * | 2015-09-25 | 2017-03-30 | 苏州立新制药有限公司 | 库潘尼西的制备方法 |
CN108884496A (zh) * | 2016-02-01 | 2018-11-23 | 拜耳制药股份公司 | Copanlisib生物标志物 |
Also Published As
Publication number | Publication date |
---|---|
CN105130998B (zh) | 2017-07-28 |
KR102104957B1 (ko) | 2020-04-28 |
WO2017049983A1 (zh) | 2017-03-30 |
KR20180096572A (ko) | 2018-08-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2021261879B2 (en) | Synthesis of N-(heteroaryl)-pyrrolo[2,3-d]pyrimidin-2-amines | |
ES2794639T3 (es) | Forma cristalina, método de preparación y compuesto intermedio de compuesto con anillo dihidropirido | |
AU2019400110B2 (en) | Radioactive fluorine-labeled Larotrectinib compound and preparation method therefor | |
CN110627801B (zh) | 一类hdac抑制剂及其用途 | |
CN107573333B (zh) | 替格瑞洛的中间体及其制备方法和替格瑞洛的制备方法 | |
CN105753944B (zh) | 达卡他韦及其衍生物的制备中间体 | |
ES2837361T3 (es) | Proceso para preparar compuestos de indol-carboxamida | |
CN105130998A (zh) | 库潘尼西的制备方法 | |
CN106749259A (zh) | 一种环戊基嘧啶并吡咯类化合物的合成方法 | |
CN104910158A (zh) | 具有生物活性的5,6,7,8-四氢吡啶并[3,4-d]嘧啶化合物及其制备方法和应用 | |
CA3129936A1 (en) | Method for preparing 1-(4-(4-(3,4-dichloro-2-fluorophenylamino)-7-methoxyquinazolin-6-yloxy)piperidin-1-yl)prop-2-en-1-one | |
CN107814804A (zh) | 依鲁替尼的制备方法 | |
CN105273023A (zh) | 一种阿糖胞苷5’-o-l-缬氨酸酯盐酸盐的制备方法 | |
CN105130997A (zh) | 一种库潘尼西的制备方法 | |
CN105985317B (zh) | 一种色瑞替尼的制备方法及其中间体 | |
CN114437113B (zh) | 一种噻唑并吡啶环联三氮唑类化合物及其制备方法和应用 | |
CN104725292A (zh) | 一种(s)(-)-氨磺必利的制备方法 | |
EP3275882B1 (en) | Process of synthesizing substituted pyridine and pyrimidine compound | |
CN104030958A (zh) | 一种(s)-1-(2-氯乙酰基)吡咯烷-2-甲腈的合成方法 | |
KR20210049130A (ko) | 세고리식 화합물의 결정 형태 및 이의 용도 | |
EP3257851A1 (en) | Salt form and crystal form of 1,2,5 thiadiazolidin-1,1-dioxide, preparation method thereof and intermediate | |
CN117343125B (zh) | 一种抗体偶联药物连接子的合成方法 | |
Zych et al. | The effect of substitution patterns on the release rates of opioid peptides DADLE and [Leu5]-enkephalin from coumarin prodrug moieties | |
CN113999238B (zh) | 一种环-反-4-l-羟脯氨酰基-l-丝氨酸-o-氨基酸酯盐酸盐的制备方法 | |
CN112159462B (zh) | 柯义巴肽a衍生物及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20200714 Address after: Hu Suzhou high tech Zone of Jiangsu province 215151 City Road No. 21 Tang Guan District Patentee after: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd. Address before: 215151 No. 21 West Tong Road, hi tech Development Zone, Jiangsu, Suzhou Co-patentee before: Xu Xuenong Patentee before: SUZHOU LIXIN PHARMACEUTICAL Co.,Ltd. |
|
TR01 | Transfer of patent right |